17 results on '"Sator, Paul"'
Search Results
2. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis
- Author
-
Graier, Thomas, Weger, Wolfgang, Sator, Paul-Gunther, Salmhofer, Wolfgang, Gruber, Barbara, Jonak, Constanze, Kölli, Claudia, Schütz-Bergmayr, Martina, Vujic, Igor, Ratzinger, Gudrun, Häring, Nina, Painsi, Clemens, Prillinger, Knut, Mlynek, Alexander, Skvara, Hans, Trattner, Hannes, Tanew, Adrian, Lichem, Roland, Ellersdorfer, Christina, Legat, Franz, Gruber-Wackernagel, Alexandra, Hofer, Angelika, Schmiedberger, Erich, Hoetzenecker, Wolfram, Müllegger, Robert, Saxinger, Werner, Quehenberger, Franz, and Wolf, Peter
- Published
- 2021
- Full Text
- View/download PDF
3. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
- Author
-
Jonak, Constanze, primary, Göttfried, Isolde, additional, Perl-Convalexius, Sylvia, additional, Gruber, Barbara, additional, Schütz-Bergmayr, Martina, additional, Vujic, Igor, additional, Weger, Wolfgang, additional, Schicher, Nikolaus, additional, Semlin, Lydia, additional, Hemetsberger, Margit, additional, Cordey, Myriam, additional, and Sator, Paul, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Dupilumab-Induced Lichen Planus: A Case with Oral and Cutaneous Eruptions
- Author
-
Kern, Laura, primary, Kleinheinrich, Luisa, additional, Feldmann, Robert, additional, Sator, Paul, additional, Stella, Alexander, additional, and Breier, Friedrich, additional
- Published
- 2022
- Full Text
- View/download PDF
5. sj-docx-1-taj-10.1177_20406223231152785 – Supplemental material for Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
- Author
-
Jonak, Constanze, Göttfried, Isolde, Perl-Convalexius, Sylvia, Gruber, Barbara, Schütz-Bergmayr, Martina, Vujic, Igor, Weger, Wolfgang, Schicher, Nikolaus, Semlin, Lydia, Hemetsberger, Margit, Cordey, Myriam, and Sator, Paul
- Subjects
FOS: Psychology ,110203 Respiratory Diseases ,FOS: Clinical medicine ,Cardiology ,170199 Psychology not elsewhere classified ,111702 Aged Health Care ,FOS: Health sciences ,110319 Psychiatry (incl. Psychotherapy) ,110306 Endocrinology ,110308 Geriatrics and Gerontology ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,110904 Neurology and Neuromuscular Diseases - Abstract
Supplemental material, sj-docx-1-taj-10.1177_20406223231152785 for Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study by Constanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, Barbara Gruber, Martina Schütz-Bergmayr, Igor Vujic, Wolfgang Weger, Nikolaus Schicher, Lydia Semlin, Margit Hemetsberger, Myriam Cordey and Paul Sator in Therapeutic Advances in Chronic Disease
- Published
- 2023
- Full Text
- View/download PDF
6. sj-docx-2-taj-10.1177_20406223231152785 – Supplemental material for Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
- Author
-
Jonak, Constanze, Göttfried, Isolde, Perl-Convalexius, Sylvia, Gruber, Barbara, Schütz-Bergmayr, Martina, Vujic, Igor, Weger, Wolfgang, Schicher, Nikolaus, Semlin, Lydia, Hemetsberger, Margit, Cordey, Myriam, and Sator, Paul
- Subjects
FOS: Psychology ,110203 Respiratory Diseases ,FOS: Clinical medicine ,Cardiology ,170199 Psychology not elsewhere classified ,111702 Aged Health Care ,FOS: Health sciences ,110319 Psychiatry (incl. Psychotherapy) ,110306 Endocrinology ,110308 Geriatrics and Gerontology ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,110904 Neurology and Neuromuscular Diseases - Abstract
Supplemental material, sj-docx-2-taj-10.1177_20406223231152785 for Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study by Constanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, Barbara Gruber, Martina Schütz-Bergmayr, Igor Vujic, Wolfgang Weger, Nikolaus Schicher, Lydia Semlin, Margit Hemetsberger, Myriam Cordey and Paul Sator in Therapeutic Advances in Chronic Disease
- Published
- 2023
- Full Text
- View/download PDF
7. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis
- Author
-
van Huizen, Astrid M., Menting, Stef P., Gyulai, Rolland, Iversen, Lars, van der Kraaij, Gayle E., Middelkamp-Hup, Maritza A., Warren, Richard B., Spuls, Phyllis I., Schejtman, Adrián A., Egeberg, Alexander, Firooz, Alireza, Kumar, Alur S., Oakley, Amanda, Foulkes, Amy, Ramos, Andrea Machado Coelho, Fougerousse, Anne-Claire, Čarija, Antoanela, Akman-Karakaş, Ayse, Horváth, Barbara, Fábos, Béata, Matlock, Benjamin Hidalgo, Claréus, Birgitta Wilson, Castro, Carla, Ferrándiz, Carlos, Correa, Carolina Cortés, Marchesi, Carolina, Goujon, Catherine, Gonzalez, Cesar, Maldonado-García, César, Hong, Chih-ho, Griffiths, Christopher E.M., Vestergaard, Christian, Echeverría, Christina Mariela, de la Cruz, Claudia, Conrad, Curdin, Törőcsik, Dániel, Drvar, Daniela Ledić, Balak, Deepak, Jullien, Denis, Appelen, Diebrecht, Kim, Dong Hyun, de Jong, Elke M.G.J., El Gamal, Emad, Laffitte, Emmanuel, Mahé, Emmanuel, Sonkoly, Enikö, Colombo, Erika Páez, Vilarrasa, Eva, Willaert, Fabienne, Novoa, Farah D., Handjani, Farhad, Valenzuela, Fernando, Vílchez-Márquez, Francisco, Gonzalez, Gabriela Otero, Krisztián, Gáspár, Damiani, Giovanni, Krnjević-Pezić, Gordana, Pellerano, Graciela, Carretero, Gregorio, Hunter, Hamish J. A., Riad, Hassan, Oon, Hazel H., Boonen, Hugo P.J., Moussa, Iftin Osman, García-Doval, Ignacio, Csányi, Ildíko, Brajac, Ines, Turchin, Irina, Grozdev, Ivan, Weinberg, Jeffrey M., Nicolopoulos, Jenny, Wells, Jillian, Lambert, Jo L.W., Ingram, John R., Prinz, Jörg Christoph, de Souza Sittart, José Alexandre, Sanchez, Jose Luis, Hsiao, Josephine Pa-Fan, Castro-Ayarza, Juan Raul, Maul, Julia-Tatjana, van den Reek, Juul M.P.A., Trčko, Katarina, Barber, Kirk, Reich, Kristian, Gebauer, Kurt Aaron, Khobzei, Kuzma, Maul, Lara V., Massari, Larisa Prpić, Fardet, Laurence, le Cleach, Laurence, Misery, Laurent, Chandrashekar, Laxmisha, Muresanu, Lidia Irinel, Lecluse, Lidian, Skov, Lone, Frez, Ma. Lorna, Babić, Lucija Tomić, Puig, Lluís, Gomez, Luis Castro, Ramam, M., Dutil, Maha, El-Sayed, Mahira Hamdy, Olszewska, Malgorzata, Schram, Mandy Elvira, Franco, Manuel Dario, Llamas-Velasco, Mar, Gonçalo, Margarida, Velásquez-Lopera, Margarita M., Abad, Maria Eugenia, de Oliveira, Maria de Fátima Santos Paim, Seyger, Marieke M. B., Kaštelan, Marija, Rademaker, Marius, Sikora, Mariusz, Lebwohl, Mark, Wiseman, Marni C., Ferran, Marta, van Doorn, Martijn, Danespazhooh, Maryam, Bylaitė-Bucinskiene, Matilda, Gooderham, Melinda J., Polić, Melita Vukšić, de Rie, Menno A., Zheng, Min, Gómez-Flores, Minerva, Salleras i Redonnet, Montse, Silverberg, Nanette B., Doss, Nejib, Yawalkar, Nikhil, Chosidow, Olivier, Zargari, Omid, de la Cueva, Pablo, Fernandez-Peñas, Pablo, Cárdenas Rojas, Paola J., Gisondi, Paolo, Grewal, Parbeer, Sator, Paul, Luna, Paula Carolina, Félix, Paulo Antonio Oldani, Varela, Paulo, Holló, Péter, Cetkovska, Petra, Calzavara-Pinton, Piergiacomo, Ghislain, Pierre-Dominique, Araujo, Raquel Ruiz, Romiti, Ricardo, Kui, Róbert, Čeović, Romana, Vender, Ronald, Lafuente-Urrez, Rosario Fátima, del-Río, Rubén, Gulin, Sandra J., Handa, Sanjeev, Mahil, Satveer K., Kolalapudi, Seetharam A., Marrón, Servando E., Azimi, Seyyede Zeinab, Janmohamed, Sherief R., da Cruz Costa, Sidney Augusto, Choon, Siew Eng, Urbancek, Slavomir, Ayanlowo, Olusola, Margasin, Susana M., Wong, Tak-Wah, Mälkönen, Tarja, Hurtová, Tatiana, Reciné, Tatiana Riveros, Huldt-Nystrøm, Theis, Torres, Tiago, Liu, Tong-Yun, Leonidze, Tsira, Sharma, Vinod Kumar, Weightman, Warren, Gulliver, Wayne, Veldkamp, Wendelien, Clinical sciences, Gerontology, Surgical clinical sciences, Dermatology, Skin function and permeability, AII - Inflammatory diseases, Graduate School, APH - Quality of Care, APH - Methodology, and APH - Personalized Medicine
- Subjects
Adult ,Consensus ,International eDelphi Study ,Patients ,Methotrexate Dosing Regimen ,Dermatology ,THERAPY ,Psoriasis/therapy ,BRITISH-ASSOCIATION ,DOUBLE-BLIND ,Folic Acid ,Surveys and Questionnaires ,MANAGEMENT ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Dermatovenerologija ,SYSTEMIC TREATMENT ,Humans ,Psoriasis ,610 Medicine & health ,Child ,Methotrexate ,methotrexate in psoriasis ,Other Research Radboud Institute for Health Sciences [Radboudumc 0] ,EFFICACY ,RANDOMIZED-TRIAL ,DERMATOLOGISTS GUIDELINES ,Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] ,CHRONIC PLAQUE PSORIASIS ,MODERATE ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Dermatovenerology - Abstract
Contains fulltext : 251813.pdf (Publisher’s version ) (Closed access) IMPORTANCE: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide. OBJECTIVE: To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics. DESIGN, SETTING, AND PARTICIPANTS: Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience). MAIN OUTCOMES AND MEASURES: In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree. RESULTS: Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients. CONCLUSIONS AND RELEVANCE: In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis.
- Published
- 2022
8. Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
- Author
-
Klein, Toni Maria, primary, Blome, Christine, additional, Kleyn, C. Elise, additional, Conrad, Curdin, additional, Sator, Paul G., additional, Ståhle, Mona, additional, Eyerich, Kilian, additional, Radtke, Marc Alexander, additional, Bundy, Christine, additional, Cordey, Myriam, additional, Griffiths, Christopher E. M., additional, and Augustin, Matthias, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it
- Author
-
Graier, Thomas, Fink-Puches, Regina, Porkert, Stephanie, Lang, Roland, Pöchlauer, Sophie, Ratzinger, Gudrun, Tanew, Adrian, Selhofer, Sylvia, Sator, Paul-Gunther, Hofer, Angelika, Gruber-Wackernagel, Alexandra, Legat, Franz J., Vieyra-Garcia, Pablo Augusto, Quehenberger, Franz, and Wolf, Peter
- Subjects
lcsh:R5-920 ,quality of life ,mycosis fungoides ,depression ,Medicine ,anxiety ,lcsh:Medicine (General) ,humanities ,PUVA ,Original Research ,phototherapy - Abstract
Background: Little is known about psychological discomfort and quality of life (QoL) in early stage mycosis fungoides (MF) and the effect of psoralen plus UV-A (PUVA) on it. Objective: To evaluate QoL, anxiety, and depression with validated instruments in early stage MF patients and whether PUVA treatment improves it. Methods: Patients with stage IA to IIA MF were treated with PUVA twice weekly for 12–24 weeks, followed by maintenance treatment or not, in a prospective randomized clinical trial. Patients completed a questionnaire on DLQI as well as the Hospital Anxiety and Depression Scale (HADS) prior to therapy, after their last PUVA exposure, and after the PUVA maintenance or observance phase. Results: For 24 patients with early stage MF, completed questionnaires were available and analyzed. Prior to treatment, 17% reported strong (DLQI > 10) and 29% moderate impairment (DLQI 6–10) in QoL; 33% of patients reported HADS scores indicating anxiety, and 21% reported scores indicating depression. PUVA significantly improved overall QoL by reducing mean DLQI scores by 58.6% (p = 0.003), HADS-A by 30% (p = 0.045), and HADS-D by 44% (p = 0.002). Improvements in QoL and psychological well-being seemed to be sustained, irrespective of maintenance treatment or not. Limitations: Small sample size. Conclusions: PUVA sustainably improves QoL and psychological well-being in patients with early stage MF. Clinical trial registration: ClinicalTrials.gov identifier: NCT01686594.
- Published
- 2020
10. Auricular electro-acupuncture as an additional perioperative analgesic method during oocyte aspiration in IVF treatment
- Author
-
Sator-Katzenschlager, Sabine M., Wölfler, Monika M., Kozek-Langenecker, Sibylle A., Sator, Kathrin, Sator, Paul-G., Li, Borwen, Heinze, Georg, and Sator, Michael O.
- Published
- 2006
11. Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides
- Author
-
Sophie Pöchlauer, Regina Fink-Puches, Sylvia Selhofer, Rachael A. Clark, Gudrun Ratzinger, Lorenzo Cerroni, Franz J. Legat, Franz Quehenberger, VijayKumar Patra, Roland Lang, Stefanie Porkert, Alexandra Gruber-Wackernagel, Peter Wolf, Adrian Tanew, Sator Paul-Gunther, Angelika Hofer, and Pablo A. Vieyra-Garcia
- Subjects
Adult ,Male ,medicine.medical_specialty ,Skin Neoplasms ,Time Factors ,Population ,Dermatology ,law.invention ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Mycosis Fungoides ,0302 clinical medicine ,Maintenance therapy ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Prospective Studies ,Prospective cohort study ,Adverse effect ,education ,PUVA Therapy ,Aged ,Aged, 80 and over ,Mycosis fungoides ,education.field_of_study ,business.industry ,Middle Aged ,medicine.disease ,Regimen ,Treatment Outcome ,Austria ,030220 oncology & carcinogenesis ,Female ,business ,Biomarkers - Abstract
Importance Psoralen-UV-A (PUVA) photochemotherapy is standard first-line treatment for skin-limited, early-stage mycosis fungoides capable of producing high initial complete response (CR) rates. However, much remains unknown about PUVA's therapeutic mechanisms, optimal duration and frequency of treatment, dose escalation, or use as maintenance therapy. Objectives To evaluate low-dose, low-frequency PUVA, and whether maintenance treatment extends disease-free remission in patients with mycosis fungoides. Design, setting, and participants This prospective randomized clinical trial with defined PUVA dosing regimen was carried out in 5 centers (Graz, Vienna, Hietzing, Innsbruck, and Salzburg) across Austria. Patients with stage IA to IIA mycosis fungoides (n = 27) were enrolled in the study beginning March 13, 2013, with the last patient enrolled March 21, 2016. These patients were treated with oral 8-methoxypsoralen followed by UV-A exposure 2 times per week for 12 to 24 weeks until CR. Patients with CR were randomized to PUVA maintenance for 9 months (14 total exposures) or no maintenance. The study was conducted from April 27, 2012, to July 27, 2018. Data analysis of the primary end point was of the intention-to-treat population, and the secondary end point analysis was of the evaluable population. Main outcomes and measures Efficacy of the PUVA regimen was determined by the rate of CR as defined by a modified severity-weighted assessment tool (mSWAT) score reduction to 0. Levels of proinflammatory molecules in serum and histologic features and percentage of clonal T cells in skin were assessed to search for biomarkers of clinical response. Results In 27 patients with mycosis fungoides, 19 (70%) were male with mean (range) age 61 (30-80) years. At baseline, patients with CR had a mean (range) mSWAT score of 18.6 (1-66) compared with 16.8 (3-46) in patients with partial response. The 12- to 24-week PUVA induction regimen reduced the mSWAT score in all patients and led to CR in 19 (70%) of 27 patients and a low mean cumulative UV-A dose of 78.5 J/cm2. The subsequent standardized 9-month PUVA maintenance phase prolonged median (range) disease-free remission from 4 (1-20) months to 15 (1-54) months (P = .02). High density of histologic infiltrate and high percentage of clonal TCR sequences in skin biopsy specimens at baseline were inversely associated with therapeutic response. No severe adverse effects were seen during the PUVA induction or maintenance phase. Conclusions and relevance This proof-of-concept study identifies potential biomarkers for therapeutic response to PUVA in mycosis fungoides; it also demonstrates that low-dose, low-frequency PUVA appears to be highly effective, and maintenance treatment may extend disease-free remission. Trial registration ClinicalTrials.gov identifier: NCT01686594.
- Published
- 2019
12. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience
- Author
-
Sator, Paul, primary
- Published
- 2018
- Full Text
- View/download PDF
13. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
- Author
-
INZINGER, Martin, WIPPEL-SLUPETZKY, Katharina, WEGER, Wolfgang, RICHTER, Leo, MLYNEK, Alexander, FLEISCHANDERL, Barbara, SCHEURECKER, Christine, SANDOR, Nicolaus, MAIRHOFER, Daniela, SATOR, Paul G., MOSER-OBERTHALER, Sabine, HÄRING, Nina, VIZNEROVA, Petra, PAINSI, Clemens, TANEW, Adrian, PONHOLZER, Peter, TATARSKI, Rafaella, BRENNER, Wilhelm, STINGL, Georg, and SALMHOFER, Wolfgang
- Subjects
PSORIASIS treatment ,DRUG efficacy ,TUMOR necrosis factors ,ADALIMUMAB ,INFLIXIMAB ,ETANERCEPT - Abstract
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p = 2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Skin treatments and dermatological procedures to promote youthful skin
- Author
-
Sator, Paul G, primary
- Published
- 2006
- Full Text
- View/download PDF
15. Schönlein-Henoch purpura during pregnancy with successful outcome for mother and newborn
- Author
-
Feldmann, Robert, primary, Rieger, Walter, additional, Sator, Paul G, additional, Gschnait, Friedrich, additional, and Breier, Friedrich, additional
- Published
- 2002
- Full Text
- View/download PDF
16. Schönlein-Henoch purpura during pregnancy with successful outcome for mother and newborn.
- Author
-
Feldman, Robert, Rieger, Walter, Sator, Paul G., Gschnait, Freidrich, and Breier, Friedrich
- Subjects
PURPURA (Pathology) ,PREGNANCY ,VASCULITIS ,ADRENOCORTICAL hormones ,MOTHERS ,NEWBORN infants - Abstract
Background: Schönlein-Henoch purpura is a systemic vasculitis that affects vessels of a small caliber and rarely reported in the literature. Case presentation: We report on a 35-year-old woman who developed palpable purpura with necrotizing cutaneous lesions on the lower limbs at 27 weeks of gestation. She also complained of epigastric pain and arthralgias. Histologic examination of a skin biopsy showed leukocytoclastic vasculitis with intravascular fibrin thrombi. The direct immunofluorescence analysis evidenced vascular deposits of IgA and C3 in the upper and mid-dermis. These findings were consistent with Schönlein-Henoch purpura. There was no evidence of renal involvement or placental dysfunction. The patient was treated with low-dose oral corticosteroids and a healthy infant was delivered by cesarean section. Examination of the placenta and the navel string disclosed no signs of vasculitis or infarction. Conclusions: Schönlein-Henoch purpura is rarely reported in pregnancy. Treatment with orally administred corticosteroids may lead to a beneficial outcome for mother and newborn. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
17. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.
- Author
-
Graier T, Weger W, Sator PG, Salmhofer W, Gruber B, Jonak C, Kölli C, Schütz-Bergmayr M, Vujic I, Ratzinger G, Häring N, Painsi C, Prillinger K, Mlynek A, Skvara H, Trattner H, Tanew A, Lichem R, Ellersdorfer C, Legat F, Gruber-Wackernagel A, Hofer A, Schmiedberger E, Hoetzenecker W, Müllegger R, Saxinger W, Quehenberger F, and Wolf P
- Abstract
Background: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions., Objective: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction., Methods: This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry., Results: Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively., Limitations: Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment., Conclusion: Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years., (© 2020 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.